Cargando…

Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer

SIMPLE SUMMARY: HER2+ and triple negative breast cancers are widely known for their aggressiveness, frequent resistance to treatment and poor prognosis. Neoadjuvant management has provided promising results for both subtypes, but there is still a subset of patients with no or low response. Consequen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pons, Laura, Hernández, Laura, Urbizu, Aintzane, Osorio, Paula, Rodríguez-Martínez, Paula, Castella, Eva, Muñoz, Ana, Sanz, Carolina, Arnaldo, Laura, Felip, Eudald, Quiroga, Vanesa, Tapia, Gustavo, Margelí, Mireia, Fernandez, Pedro Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296027/ https://www.ncbi.nlm.nih.gov/pubmed/37370679 http://dx.doi.org/10.3390/cancers15123068

Ejemplares similares

Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
por: Pons, Laura, et al.
Publicado: (2022)

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
por: Ferrando-Díez, Angelica, et al.
Publicado: (2022)

Obtaining miRNA from Saliva—Comparison of Sampling and Purification Methods
por: Urbizu, Aintzane, et al.
Publicado: (2023)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients
por: Hardy-Werbin, Max, et al.
Publicado: (2019)

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
por: Margeli, Mireia, et al.
Publicado: (2010)

Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy
por: Urbizu, Aintzane, et al.
Publicado: (2020)

Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinson’s Disease
por: Marsal-García, Laura, et al.
Publicado: (2021)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis
por: Gutiérrez-Chamorro, Lucía, et al.
Publicado: (2023)

Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types
por: Felip, Eudald, et al.
Publicado: (2022)

God Help Her
por: McCarroll, James
Publicado: (1892)

Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy
por: Castellví, Marc, et al.
Publicado: (2020)

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer
por: Romeo, Margarita, et al.
Publicado: (2018)

Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer
por: Vila, Mireia Margelí, et al.
Publicado: (2020)

Erratum: Castellví, M. et al. Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy. Cancers 2020, 12, 713
por: Castellví, Marc, et al.
Publicado: (2020)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
por: Rediti, Mattia, et al.
Publicado: (2023)

Chiari Malformation Type I: A Case-Control Association Study of 58 Developmental Genes
por: Urbizu, Aintzane, et al.
Publicado: (2013)

Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: A prospective observational study
por: Solá, Montserrat, et al.
Publicado: (2011)

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies
por: Krawczyk, Natalia, et al.
Publicado: (2022)

Multidimensional Biomechanics-Based Score to Assess Disease Progression in Duchenne Muscular Dystrophy
por: Migliorelli, Carolina, et al.
Publicado: (2023)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients
por: Dehghani, Mehdi, et al.
Publicado: (2020)

Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not
por: Jeong, Young-Hoon, et al.
Publicado: (2021)

Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case–control study
por: Sui, Lin, et al.
Publicado: (2023)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial
por: Crocamo, Susanne, et al.
Publicado: (2019)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors
por: Chica-Parrado, María Rosario, et al.
Publicado: (2020)

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
por: Spring, Laura M., et al.
Publicado: (2022)

Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data
por: Bernat-Peguera, Adrià, et al.
Publicado: (2022)

The Mother's Help and Guide to the Domestic Management of Her Children
Publicado: (1894)

The Mother's Help and Guide to the Domestic Management of Her Children
Publicado: (1894)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022)

Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer
por: Sevcikova, Katarina, et al.
Publicado: (2013)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
por: Cirauqui, Beatriz Cirauqui, et al.
Publicado: (2014)

Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer
por: Crocamo, Susanne, et al.
Publicado: (2022)

HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis
por: Cao, Guo-dong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9a8ishcvmvu7a9vpjsghbcm1d1